Peri-interventional antibiotic prophylaxis in endoscopic valve implantation for lung volume reduction in COPD patients: results from a German multicenter observational cohort - Scorecard - MDSpire

Peri-interventional antibiotic prophylaxis in endoscopic valve implantation for lung volume reduction in COPD patients: results from a German multicenter observational cohort

  • By

  • Eva Pappe

  • Hadis Darvishi

  • Thomas Sgarbossa

  • Jacopo Saccomano

  • Kaid Darwiche

  • Stefan Andreas

  • Stephan Eisenmann

  • Bernd Schmidt

  • Wolfgang Gesierich

  • Nicolas Dickgreber

  • Christian Geltner

  • Joachim Hans Ficker

  • Angelique Holland

  • Björn Schwick

  • Stephan Eggeling

  • Ralf Eberhardt

  • Christian Grah

  • Christoph Hünermann

  • Urte Sommerwerck

  • Andreas Fertl

  • Sylke Kurz

  • Peter Schramm

  • Dinah von Schöning

  • Leif Erik Sander

  • Martin Witzenrath

  • Ralf-Harto Hübner

  • February 13, 2026

  • 0 min

Share

Clinical Scorecard: Antibiotic Prophylaxis During Endoscopic Valve Implantation for Lung Volume Reduction in COPD Patients: Findings from a Multicenter Observational Study in Germany

At a Glance

CategoryDetail
ConditionSevere COPD with advanced emphysema undergoing endoscopic lung volume reduction (ELVR)
Key MechanismsBronchoscopic implantation of one-way valves to induce atelectasis of diseased lung regions
Target PopulationPatients with severe COPD and advanced emphysema considered for ELVR
Care SettingMulticenter specialized pulmonary centers performing bronchoscopic ELVR

Key Highlights

  • ELVR improves lung function, exercise capacity, dyspnea, and quality of life in severe COPD patients.
  • Peri-interventional antibiotic prophylaxis is commonly used but lacks conclusive evidence of clinical benefit.
  • Current German guidelines do not recommend routine antibiotic prophylaxis for bronchoscopic procedures.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of severe COPD with advanced emphysema should be confirmed prior to ELVR.
  • Microbiological sampling of bronchial aspirates or lavage fluid prior to ELVR is recommended for infection assessment.

Management

  • ELVR with endobronchial valves is an established treatment for selected severe COPD patients.
  • Peri-interventional antibiotic prophylaxis is frequently administered but not standardized and varies by center.
  • Antibiotic regimens include single-dose prophylaxis during procedure or prolonged 5–7-day courses, commonly with cephalosporins or fluoroquinolones.

Monitoring & Follow-up

  • Monitor for procedure-related adverse events including pneumonia and acute exacerbations of COPD within 3 months post-ELVR.
  • Assess lung function, exercise capacity, and symptom scores at baseline and 3 months post-procedure.
  • Length of hospital stay should be recorded as an outcome measure.

Risks

  • Potential risks include acute exacerbations and infections requiring early valve removal.
  • Routine antibiotic prophylaxis may not reduce these risks and is not currently guideline-recommended.

Patient & Prescribing Data

Severe COPD patients undergoing ELVR with endobronchial valves in Germany

Antibiotic prophylaxis strategies vary widely; no conclusive evidence supports routine use to reduce complications or improve short-term outcomes.

Clinical Best Practices

  • Careful patient selection for ELVR based on severity and emphysema distribution.
  • Consider microbiological assessment prior to valve implantation to guide infection risk.
  • Individualize antibiotic prophylaxis decisions based on local protocols and patient risk factors.
  • Close monitoring for post-procedural infections and exacerbations is essential.
  • Adhere to ethical standards and informed consent in registry-based observational studies.

References

Original Source(s)

Peri-interventional antibiotic prophylaxis in endoscopic valve implantation for lung volume reduction in COPD patients: results from a German multicenter observational cohort

  • by Eva Pappe, Hadis Darvishi, Thomas Sgarbossa, Jacopo Saccomano, Kaid Darwiche, Stefan Andreas, Stephan Eisenmann, Bernd Schmidt, Wolfgang Gesierich, Nicolas Dickgreber, Christian Geltner, Joachim Hans Ficker, Angelique Holland, Björn Schwick, Stephan Eggeling, Ralf Eberhardt, Christian Grah, Christoph Hünermann, Urte Sommerwerck, Andreas Fertl, Sylke Kurz, Peter Schramm, Dinah von Schöning, Leif Erik Sander, Martin Witzenrath, Ralf-Harto Hübner

  • February 13, 2026

Related Content

Broad-spectrum targeted next-generation sequencing: is it ready for routine deployment in intensive care units for severe pneumonia?

Early Enteral Feeding Tied to Fewer Complications

Benefit driven by fewer infections and pulmonary events, though overall complication rates were similar

CDC Lists Dozens of Infectious Disease Tests as Unavailable

More than two dozen assays paused or discontinued, with alternative testing options noted